Analytical Data
-
基因名
GLP1
- Application
-
别名
GLP1；Glucagon-like peptide 1 receptor
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P01275
-
表达区间
53-89aa
-
氨基酸序列
HSQGTFTSDYSKYLDSRRAQDFVQWLMNTKRNRNNIA
-
分子量
30 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GLP-1 (glucagon-like peptide-1) is an incretin hormone that plays a crucial role in glucose metabolism and appetite regulation. Originally discovered in the 1980s, GLP-1 is secreted by the intestinal L-cells in response to nutrient intake and stimulates insulin secretion while inhibiting glucagon release, thereby lowering blood glucose levels. Due to its multifaceted role in glucose homeostasis and potential neuroprotective effects, GLP-1 has become a focal point in diabetes research. Recombinant GLP-1 proteins and analogs have been developed to enhance its stability and bioactivity, addressing challenges like rapid degradation in the bloodstream. These synthetic molecules, such as exenatide and liraglutide, have demonstrated efficacy in not only controlling blood sugar in Type 2 diabetes patients but also in promoting weight loss. Additionally, ongoing research is exploring their potential therapeutic benefits in other conditions, including obesity and neurodegenerative diseases. The development of GLP-1 receptor agonists marks a significant advancement in diabetes management, leading to a better understanding of metabolic disorders and opening avenues for innovative pharmaceutical interventions.
